Impact of COVID-19 pandemic on diagnosis and prognosis of LC

• Date : 2021-01-29
• 12    
  0

Targeted therapies in lung cancer

• Date : 2021-01-29
• 4    
  0

CONFIRM trial: nivolumab in relapsed malignant mesothelioma

• Date : 2021-01-29
• 1    
  0

NGS key for optimal lung cancer treatment

• Date : 2021-01-29
• 1    
  0

KRAS-mutant NSCLC: CodeBreak 100 trial of sotorasib

• Date : 2021-01-29
• 0    
  0

Lung cancer detection rates in Manchester

• Date : 2021-01-29
• 0    
  0

Advances in perioperative immunotherapy in lung cancer

• Date : 2021-01-29
• 0    
  0

Phase III METIS: Tumor treating fields following radiosurgery for brain mets

• Date : 2021-01-29
• 0    
  0

LCMC3 primary analysis: Neoadjuvant atezolizumab in NSCLC

• Date : 2021-01-29
• 0    
  0

CHRYSALIS: Amivantamab for EGFR exon 20 insertion mutant NSCLC

• Date : 2021-01-29
• 0    
  0

Updates in ALK+ lung cancer: GLASS, ALEX, ALTA-1L and CROWN

• Date : 2021-01-29
• 0    
  0

Raising the bar in radiation oncology: what does the future hold?

• Date : 2021-01-29
• 0    
  0

Bringing clinical trials to communities

• Date : 2021-01-29
• 0    
  0

What are tumor treating fields?

• Date : 2021-01-29
• 0    
  0

Bioradon France: levels of radon and prevalence of driver alterations in NSCLC

• Date : 2021-01-29
• 0    
  0

KEYNOTE-189 update: 4-year follow-up of FL pembro +chemo metastatic NSCLC

• Date : 2021-01-29
• 0    
  0

Phase II CodeBreak 100 trial of sotorasib in advanced NSCLC

• Date : 2021-01-29
• 0    
  0

DENIM: dendritic cell maintenance therapy in mesothelioma

• Date : 2021-01-29
• 0    
  0

Clinical trials of neoadjuvant targeted therapy in resectable NSCLC

• Date : 2021-01-29
• 0    
  0

BFAST: High dose alectinib for RET-positive NSCLC

• Date : 2021-01-29
• 0    
  0

Evidence-based approaches to smoking cessation

• Date : 2021-01-29
• 0    
  0

Impact of autoimmune disease co-occurring with thymic epithelial tumors and Good’s syndrome

• Date : 2021-01-29
• 0    
  0

Efficacy of datopotamab deruxtecan, a TROP2 ADC, in aNSCLC

• Date : 2021-01-29
• 0    
  0

The importance of determining 'value' in radiation oncology

• Date : 2021-01-29
• 0    
  0

The rise of telemedicine: Impact on cancer care and patient satisfaction

• Date : 2021-01-29
• 0    
  0

Comparing risk discrimination performance of lung cancer risk models

• Date : 2021-01-29
• 0    
  0

ccfDNA to monitor the biological course of thymic epithelial tumors

• Date : 2021-01-29
• 0    
  0

How does treatment-associated financial distress change over time?

• Date : 2021-01-29
• 0    
  0

Interim results from DESTINY-Lung01: T-DXd in HER2-overexpressing NSCLC

• Date : 2021-01-29
• 0    
  0

Moving forward: targeted therapies in early-stage lung cancer

• Date : 2021-01-29
• 0    
  0

Cemiplimab efficacy by PD-L1 expression in the EMPOWER-Lung1 trial of NSCLC

• Date : 2021-01-29
• 0    
  0

Atezo maintenance therapy improves survival in the IMpower133 trial of ES-SCLC

• Date : 2021-01-29
• 0    
  0

CodeBreak 100: sotorasib in KRAS-mutated NSCLC

• Date : 2021-01-29
• 0    
  0

VISION trial: subset efficacy analyses of tepotinib for NSCLC

• Date : 2021-01-29
• 0    
  0

IASC WCLC 2021: CX-2029 and AMG 757 for lung cancer

• Date : 2021-01-29
• 0    
  0

Key lung cancer updates: KRAS(G12C) inhibitors and ADCs

• Date : 2021-01-29
• 0    
  0

The challenges of treating METex14 NSCLC

• Date : 2021-01-29
• 0    
  0

Pembro +/- ipi in metastatic NSCLC: KEYNOTE-598

• Date : 2021-01-29
• 0    
  0

NICE approval: brigatinib in ALK NSCLC

• Date : 2021-01-29
• 0    
  0

Updated results from the CASPIAN trial of durvalumab plus chemo in SCLC

• Date : 2021-01-29
• 0    
  0

KEYNOTE-598: pembro + ipi in metastatic NSCLC

• Date : 2021-01-29
• 0    
  0

Evaluating the LIPI for first line immunotherapy in NSCLC

• Date : 2021-01-29
• 0    
  0

Immunotherapy updates from WCLC 2021

• Date : 2021-01-29
• 0    
  0

Extending durvalumab maintenance to special populations

• Date : 2021-01-29
• 0    
  0

Blood-based biomarkers for immunotherapy in NSCLC

• Date : 2021-01-29
• 0    
  0

PET-boost study in NSCLC

• Date : 2021-01-29
• 0    
  0

Neratinib-based combination therapy in HER2-Mutant lung cancer

• Date : 2021-01-29
• 0    
  0

Updates from the Sarah Cannon Research Institute

• Date : 2021-01-29
• 0    
  0

Real-world data for nivo in recurrent malignant pleural mesothelioma

• Date : 2021-01-29
• 0    
  0

Lung cancer screening in the UK

• Date : 2021-01-29
• 0    
  0

ALK mutations in ctDNA predict responses to next generation ALK TKIs in NSCLC

• Date : 2021-01-29
• 0    
  0

Challenges in targeted drug development and treatment in lung cancer

• Date : 2021-01-29
• 0    
  0

Driving CAR-T forwards for solid tumors

• Date : 2021-01-29
• 0    
  0

KEYNOTE-799: pembro + chemoradiotherapy in locally advanced NSCLC

• Date : 2021-01-29
• 0    
  0

Intergrating lung cancer screening with smoking cessation

• Date : 2021-01-29
• 0    
  0

ZENITH20: poziotinib in EGFR and HER2 Exon 20 mutant NSCLC

• Date : 2021-01-29
• 0    
  0

Outcomes of patients with SCLC following surgical resection

• Date : 2021-01-29
• 0    
  0

Congrès ESMO 2026

• Date : 2026-10-23
• 10933    
  0

17ème Biennale Monégasque de Cancérologie

• Date : 2026-01-27
• 2339    
  0

24ème Cours Francophone Supérieur sur les Cancers du sein & les Cancers gynécologiques 2026

• Date : 2026-01-14
• 177    
  0

Congrès ESMO d'Immuno-Oncologie 2025

• Date : 2025-12-10
• 9368    
  0

SABCS 2025 Symposium

• Date : 2025-12-09
• 20365    
  0